- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NMLSF
Recent news which mentions NMLSF
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
From Benzinga
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
April 20, 2023
Tickers
NMLSF
From Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
From Benzinga
From Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
From Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
From Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
November 30, 2022
From Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
November 17, 2022
From Benzinga
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
September 30, 2022
From Benzinga
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
September 29, 2022
Tickers
NMLSF
From Benzinga
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
September 17, 2022
Tickers
NMLSF
From Benzinga
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
June 16, 2022
Tickers
NMLSF
From Benzinga
From Benzinga
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
June 07, 2022
Tickers
NMLSF
From Benzinga
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
February 22, 2022
From Benzinga
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
February 16, 2022
Tickers
NMLSF
From Benzinga
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
February 08, 2022
From Benzinga
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
January 27, 2022
From Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
From Benzinga
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.